Shots:
- ImaginAb to receive license fees and other contingent payments and will partner with Neuvogen to implement clinical doses of 89Zr CD8 Immuno-PET imaging agents in their clinical trials of therapeutic vaccines
- ImaginAb will provide technical, clinical & regulatory support to Neuvogen. ImaginAb’s PET imaging technology enables tracking and quantitative imaging of CD8 T cells in cancer patients
- The agreement gives Neuvogen access to highly specific and precise imaging of the presence of CD8 T Cells in solid tumors
Click here to read full press release/ article | Ref: PRNewswire | Image: PRNewswire
The post ImaginAb Signs a Multi-Year Non-Exclusive License Agreement with Neuvogen for CD8 ImmunoPET Technology first appeared on PharmaShots.
